STVN vs WST

For growth investors, West Pharmaceutical Services, Inc.

(WST) is the stronger pick with 6. 3% revenue growth year-over-year, versus 3. 2% for Stevanato Group S. p. A. (STVN). Stevanato Group S. p. A. (STVN) offers the better valuation at 31. 3x trailing P/E (29. 3x forward), making it the more compelling value choice. Analysts rate Stevanato Group S. p. A. (STVN) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Stevanato Group S.

p. A. (STVN) is the cheapest at 31. 3x versus West Pharmaceutical Services, Inc. at 47. 3x. On forward P/E, Stevanato Group S. p. A. is actually cheaper at 29. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stevanato Group S. p. A. wins at 2. 48x versus West Pharmaceutical Services, Inc. 's 4. 51x.

Over the past 5 years, West Pharmaceutical Services, Inc.

(WST) delivered a total return of -2. 4%, compared to -7. 2% for Stevanato Group S. p. A. (STVN). Over 10 years, the gap is even starker: WST returned +361. 4% versus STVN's -7. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), West Pharmaceutical Services, Inc.

(WST) is the lower-risk stock at 0. 92β versus Stevanato Group S. p. A. 's 1. 45β — meaning STVN is approximately 58% more volatile than WST relative to the S&P 500. On balance sheet safety, West Pharmaceutical Services, Inc. (WST) carries a lower debt/equity ratio of 13% versus 32% for Stevanato Group S. p. A. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), West Pharmaceutical Services, Inc.

(WST) is pulling ahead at 6. 3% versus 3. 2% for Stevanato Group S. p. A. (STVN). On earnings-per-share growth, the picture is similar: Stevanato Group S. p. A. grew EPS 14. 0% year-over-year, compared to 1. 6% for West Pharmaceutical Services, Inc.. Over a 3-year CAGR, STVN leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

West Pharmaceutical Services, Inc.

(WST) is the more profitable company, earning 16. 1% net margin versus 11. 8% for Stevanato Group S. p. A. — meaning it keeps 16. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WST leads at 20. 1% versus 16. 1% for STVN. At the gross margin level — before operating expenses — WST leads at 35. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stevanato Group S. p. A. (STVN) is the more undervalued stock at a PEG of 2. 48x versus West Pharmaceutical Services, Inc. 's 4. 51x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Stevanato Group S. p. A. (STVN) trades at 29. 3x forward P/E versus 37. 3x for West Pharmaceutical Services, Inc. — 8. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for STVN: 35. 9% to $24. 50.

All stocks in this comparison pay dividends.

Stevanato Group S. p. A. (STVN) offers the highest yield at 0. 3%, versus 0. 3% for West Pharmaceutical Services, Inc. (WST).

For long-horizon retirement investors, West Pharmaceutical Services, Inc.

(WST) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92), +361. 4% 10Y return). Both have compounded well over 10 years (WST: +361. 4%, STVN: -7. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.